Overview

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

Status:
NOT_YET_RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
Phase:
PHASE1
Details
Lead Sponsor:
Stanford University
Collaborator:
Orca Biosystems, Inc.
Treatments:
Busulfan
fludarabine
Thiotepa